Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Abeona TherapeuticsSTU:PCJ +4.32%51 Days Payable is 200.70 as of Mar. 2026, which is 67% below its 10-year median of 603.72. GuruFocus rates STU:PCJ with a GF Score™ of 51/100 and a GF Value™ of €15.12 (Possible Value Trap). The stock has 8 warning signs investors should review. Among 704 Biotechnology companies, Abeona Therapeutics ranks better than 74.15% on this metric.
The historical rank and industry rank for Abeona Therapeutics's Days Payable or its related term are showing as below:
STU:PCJ'
s Days Payable Range Over the Past 10 Years
Min: 360.67 Med: 603.72 Max: 2488.49
Current: 360.67
During the past 13 years, Abeona Therapeutics's highest Days Payable was 2488.49. The lowest was 360.67. And the median was 603.72.
STU:PCJ's Days Payable is ranked better than 74.15% of 704
companies
in the Biotechnology industry
Industry Median: 112.715
vs STU:PCJ: 360.67
Abeona Therapeutics's Days Payable
increased
from Mar. 2025 (0.00) to Mar. 2026 (200.70).
It may suggest that Abeona Therapeuticsdelayed paying its suppliers.
The historical data trend for Abeona Therapeutics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:PCJ vs RCKT, UPB, PALI: Days Payable Comparison
For the Biotechnology subindustry, Abeona Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abeona Therapeutics Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Abeona Therapeutics's Days Payable distribution charts can be found below:
* The bar in red indicates where Abeona Therapeutics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Abeona Therapeutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abeona Therapeutics (STU:PCJ) has a Days Payable of 200.70 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Abeona Therapeutics and its competitors. This is 67% below median its historical median of 603.72. Over the past decade, Abeona Therapeutics' Days Payable has ranged from 360.67 to 2,488.49. According to the industry distribution chart, Abeona Therapeutics ranks #182 out of 704 companies in the Biotechnology industry, placing it in the top 25.9%.
Is Abeona Therapeutics' Days Payable too high?
Abeona Therapeutics' current Days Payable of 200.70 is 67% below median its 10-year median of 603.72. Over the past 10 years, this metric has ranged from a low of 360.67 to a high of 2,488.49. The Biotechnology industry median Days Payable is 112.72. Abeona Therapeutics' value of 200.70 is 78.1% above this industry median. Based on the distribution chart, Abeona Therapeutics ranks #182 out of 704 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Abeona Therapeutics has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Abeona Therapeutics' Days Payable compare to RCKT and UPB?
According to the Biotechnology industry distribution chart, Abeona Therapeutics ranks #182 out of 704 companies for Days Payable. This puts Abeona Therapeutics in the upper half of its industry. The industry median Days Payable is 112.72. Abeona Therapeutics' value of 200.70 is 78.1% above this benchmark. Historically, Abeona Therapeutics' own Days Payable has ranged from 360.67 to 2,488.49 over the past decade. While the company's 10-year median is 603.72 vs. the industry median of 112.72, Abeona Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.72, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Abeona Therapeutics's current Days Payable of 200.70 is 78.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Abeona Therapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 112.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Abeona Therapeutics's current Days Payable is 200.70, which is 67% below median its own 10-year median of 603.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abeona Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Abeona Therapeutics (STU:PCJ) is currently considered Possible Value Trap. The stock's GF Value™ is €15.12, compared to a current price of €6.23 — trading 58.8% below its estimated fair value. The current Days Payable is 200.70, which is 67% below median its 10-year median of 603.72 and 78.1% above the Biotechnology industry median of 112.72. Abeona Therapeutics' overall GF Score™ is 51/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Abeona Therapeutics (STU:PCJ), the current Days Payable is 200.70 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abeona Therapeutics (STU:PCJ) Overvalued in 2026?
Based on GuruFocus' analysis, Abeona Therapeutics stock appears to be undervalued.
The current stock price of €6.23 is trading 58.8% below its estimated GF Value™ of €15.12.
GuruFocus considers Abeona Therapeutics to be Possible Value Trap.
Key valuation signals for STU:PCJ:
Days Payable: 200.70 (67% below median its 10-year median of 603.72)
GF Value™: €15.12 vs. price of €6.23 (58.8% below fair value)
Industry Position: 78.1% above the Biotechnology median (#182 of 704)
No single metric tells the full story. See the STU:PCJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
51GF Score
Get the complete analysis for STU:PCJ
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:PCJ has been successfully added to your 
